Boomi Named a Leader for Ninth Consecutive Time in Gartner® Magic Quadrant™ for Integration Platform as a Service, Worldwide
30.1.2023 19:28:00 EET | Business Wire | Press release
Boomi TM, the intelligent connectivity and automation leader, today announced that Gartner has positioned Boomi as a Leader in its Magic Quadrant for Integration Platform as a Service (iPaaS), Worldwide for the ninth consecutive time. Gartner evaluated 16 iPaaS providers on their ability to execute and completeness of vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230130005154/en/
Boomi Named a Leader for Ninth Consecutive Time in Gartner® Magic Quadrant™ for Integration Platform as a Service, Worldwide (Graphic: Business Wire)
The iPaaS market is projected to reach $11 billion in revenue by 2026.1 Given the advanced capabilities and immense scale of iPaaS vendors, [iPaaS] has become the strategic integration platform of choice for hundreds of thousands of organizations around the world. In many cases, iPaaS has replaced previous generations of integration platform software such as application integration suites, data integration tools and B2B gateway software.2
“Boomi continues to have more customers than any other cloud integration provider,” said Steve Lucas, CEO at Boomi. “Our self-managing, self-learning, and self-scaling integrations run themselves autonomously – saving more time and money over the long term. We help organizations of all sizes and industries worldwide achieve better collaboration and data-sharing as their technology environments become more fragmented and complex. That’s why our mission of digital connectedness is more important than ever for business success.”
Trusted by customers across all industries globally, for its speed, ease-of-use, and lower total cost of ownership, the cloud-native, unified, low code, scalable, open, secure, and intelligent Boomi AtomSphere™ Platform helps organizations across all industries quickly and easily accelerate business outcomes. Boomi connects everyone to everything, anywhere, by providing end-to-end capabilities, including integration, master data management, API management, workflow automation, data quality governance, B2B/EDI network management, and data catalog and preparation.
Boomi recently announced significant updates to its platform and business, including:
Product Innovation
- Rapid API Creation – Single-click creation of an API from an integration flow to rapidly expose secure services to developers.
- Federal Risk Authorization Management Program (FedRAMP) Authorization – Boomi’s low-code workflow automation service, Boomi Flow, joined other Boomi platform services that have been FedRAMP authorized since 2019, including API Management, Integration, and Master Data Hub.
- IRAP Assessment – The Boomi AtomSphere Platform was independently assessed for cloud security against the Australian Government’s Information Security Manual (ISM) PROTECTED controls. Boomi’s security posture for storing, processing, and communicating information allows government agencies to purchase the Boomi platform without needing to complete their own independent assessments.
- B2B/EDI for the Automotive Industry – Support for the ODETTE standard for faster interoperability with a customer’s automotive supply chain.
Citizen Integrator/Business Technologist Enhancements
- Expanded Boomi Discover Catalog – More pre-built recipes to simplify integration.
- Simplified Visual Experience – New iconography, dynamic and responsive user engagement that provides the foundation for an engaging user experience.
- Accelerated Product Onboarding – Platform and Welcome Pages make it easy for the citizen integrator/business technologist to launch their journey.
Expanded Leadership and Global Reach
- Leadership Expansion – Boomi recently appointed Steve Lucas as Chief Executive Officer, a 3x CEO with more than 27 years of experience leading and operating some of the world’s most innovative, global enterprise software companies. Prior to spending three years growing iCIMS, Lucas held executive roles at Adobe, Marketo, SAP, and Salesforce, and brings specific expertise and experience in data management, platform as a service, and integration. As CEO of Marketo, Lucas implemented significant product expansion and platform growth, leading to Adobe’s $4.75 billion acquisition of the company.
- Global Growth – Boomi has also been continuing to scale rapidly, recently expanding its global footprint in Japan to address growing demand across Asia-Pacific.
As a category-leading, global software as a service (SaaS) company, Boomi touts a growing community of more than 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the iPaaS space. The company boasts a worldwide network of approximately 800 partners, including Accenture, Deloitte, SAP, and Snowflake; and works with the largest hyperscaler cloud service providers, including Amazon Web Services, Google and Microsoft, among others.
Recently included on the Deloitte Technology Fast 500™ and Inc. 5000 lists as one of America’s fastest growing and most innovative technology companies, Boomi has also won two International Stevie® Awards, for Company of the Year and Product Innovation; the Gold Globee® Award in the Platform as a Service (PaaS) category; the Merit Award for Technology in the Cloud Services category; the Stratus Award as a Global Leader in Cloud Computing 2022, and received the prestigious 5-star rating in the CRN Partner Program Guide, a definitive list of the most notable programs from industry-leading technology vendors that provide innovative products and flexible services through the IT channel. Boomi has also won numerous awards for being an employer of choice, including a recent listing as one of Inc. Magazine’s Best Workplaces.
To learn more about the iPaaS market and Boomi’s recognition, read the Gartner report: “Magic Quadrant for Integration Platform as a Service, Worldwide.”
Additional Resources
- Learn more in Boomi’s latest blog post from Ed Macosky, Chief Innovation Officer
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
Gartner Disclaimer:
Gartner, Magic Quadrant for Integration Platform as a Service, Worldwide, Keith Guttridge, Andrew Comes, Saikat Ray, January 24, 2023
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organizations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, Boomiverse, and AtomSphere are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
1 Forecast: Enterprise Infrastructure Software, Worldwide, 2020-2026, 4Q22 Update
2 Gartner, Magic Quadrant for Integration Platform as a Service, Worldwide, Keith Guttridge, Andrew Comes, Saikat Ray, January 24, 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005154/en/
Contact information
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
